What researchers study
Cagrilintide is a long-acting amylin analogue investigated clinically for appetite regulation, satiety and body-weight management, both alone and in combination with semaglutide.
Research-use context: “What it is used for” below means what scientists and clinical researchers have investigated—not an instruction or recommendation for personal use.
Potential side effects & unknowns
Clinical trials have most often reported gastrointestinal effects such as nausea, constipation, diarrhea, vomiting and abdominal discomfort, along with injection-site reactions. Trial findings apply to regulated study drug—not automatically to third-party research material.
Research highlight
Unlike many peptides on this site, cagrilintide has substantial randomized human trial data. Phase 2 research reported clinically meaningful weight reduction, and later combination studies with semaglutide reported larger reductions while gastrointestinal adverse events remained common.
RESEARCH REFERENCE
Continue with the WILGO Research Library
The previously embedded third-party video is no longer available for off-site embedding. WILGO has removed it and retained the page's written research summary, references, and source information.
VIEW RESEARCH LIBRARYLooking for Cagrilintide?
Follow the tracked WILGO product link to see current inventory, exact product specifications and checkout pricing.